• Announcing the DIFICID® Co-Pay Assistance Program

    Eligible patients* can now save up to $200.00 with the DIFICID Co-Pay Assistance Program

    LEARN MORE

    *Restrictions and Conditions of Use Apply

  • Alt text of Content Fake 01

    DIFICID® (fidaxomicin) tablets Granted New Technology Add-On Payment (NTAP)

    Centers for Medicare & Medicaid Services has granted a NTAP for DIFICID administered in the inpatient hospital setting to treat Clostridium difficile-associated diarrhea (CDAD)*

    READ MORE
  • DIFICID Rx Assist™

    DIFICID Rx Assist is now available to provide reimbursement information to support patient access to DIFICID® (fidaxomicin) tablets. The reimbursement information hotline is available for patients, caregivers, physicians and healthcare provider staff to assist with reimbursement, coverage questions or patient financial support.

    READ MORE

 

 

DIFICID® is a macrolide antibacterial drug indicated in adults ≥18 years of age for treatment of Clostridium difficile-associated diarrhea.

 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile.

 

The information provided on this Web site is intended for US healthcare professionals only.

 

Important Safety Information

  • DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin
  • DIFICID should not be used for systemic infections
  • Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported. In the event of a severe reaction, discontinue DIFICID.
  • Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile.
    Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug- resistant bacteria.
  • The most common adverse reactions reported in clinical trials are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

 

Indications and Usage

  • DIFICID is a macrolide antibacterial drug indicated in adults ≥18 years of age for treatment of Clostridium difficile-associated diarrhea
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile